FARMINGDALE, N.Y., Aug. 12, 2019 (GLOBE NEWSWIRE) — Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has received Conformité Européene (CE) Mark approval for Nexus. The CE marking confirms that Nexus meets the requirements of the European Medical Devices Directive, which now …